1. |
Ogawa E, Jun DW, Toyoda H, Hsu YC, Yoon EL, Ahn SB, Yeh ML, Do S, Trinh HN, Takahashi H, Enomoto M, Kawada N, Yasuda S, Tseng CH, Kawashima K, Lee HA, Inoue K, Haga H, Do AT, Maeda M, Hoang JH, Cheung R, Ueno Y, Eguchi Y, Furusyo N, Yu ML, Tanaka Y, Nguyen MH., Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study, Alimentary Pharmacology and Therapeutics, 59, 2, 239-248, 2024.01. |
2. |
Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, Cheung R, Nguyen MH, Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C, JAMA Internal Medicine, doi:10.1001/jamainternmed.2022.5699, 183, 2, 97-105, 2023.02. |
3. |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: Week 144 results from a real-world, multicentre cohort study, Alimentary Pharmacology and Therapeutics, doi:10.1111/apt.17107, 56, 4, 713-722, 2022.08. |
4. |
Ogawa E, Nakamuta M, Koyanagi T, Ooho A, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Satoh T, Takahashi K, Azuma K, Yamashita N, Yamashita N, Sugimoto R, Amagase H, Kuniyoshi M, Ichiki Y, Morita C, Kato M, Shimoda S, Nomura H, Hayashi J, Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study, Hepatology International, doi:10.1007/s12072-021-10295-3, 16, 2, 282-293, 2022.04. |
5. |
Ogawa E, Kawano A, Ooho A, Furusyo N, Satoh T, Takahashi K, Kajiwara E, Dohmen K, Nakamuta M, Azuma K, Koyanagi T, Yamashita N, Yanagita K, Ichiki Y, Kuniyoshi M, Yamashita N, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J, Long-term hepatic function of patients with compensated cirrhosis following successful direct-acting antiviral treatment for HCV infection, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.15703, 37, 2, 371-377, 2022.02. |
6. |
Ogawa E, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Yamashita N, Ichiki Y, Yamashita N, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Nomura H, Hayashi J, Long-term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct-acting antivirals, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.15659, 37, 1, 190-199, 2022.01. |
7. |
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C, Cancers, 12, 9, E2602, 2020.09. |
8. |
Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K, Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination, Alimentary Pharmacology and Therapeutics, 52, 5, 866-876, 2020.09. |
9. |
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Takahashi K, Satoh T, Koyanagi T, Ichiki Y, Kuniyoshi M, Yanagita K, Amagase H, Morita C, Sugimoto R, Kato M, Shimoda S, Hayashi J, Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals, The Journal of Infectious Disease, doi:org/10.1093/infdis/jiaa359, 226, 3, 431-440, 2022.08. |
10. |
Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J, Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B, Liver International, 40, 7, 1578-1589, 2020.07. |
11. |
Eiichi Ogawa, Yee Hui Yeo, Nolan Dang, Michael H. Le, Donghak Jeong, Sally Tran, Linda Henry, Ramsey Cheung, Mindie H. Nguyen, Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States, JAMA Network Open, 3, 4, e201844, 2020.04. |
12. |
Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH, HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication, Clinical Infectious Diseases, 71, 11, 2840-2848, 2020.12. |
13. |
Ogawa E, Nomura H, Nakamuta M, Kawano A, Dohmen K, Kajiwara E, Satoh T, Koyanagi T, Takahashi K, Ooho A, Azuma K, Furusyo N, Kato M, Shimoda S, Hayashi J, Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis, Hepatology Research, 50, 2, 174-181, 2020.02. |
14. |
Ogawa E, Furusyo N, Nakamuta M, Nomura H, Satoh T, Takahashi K, Koyanagi T, Kajiwara E, Dohmen K, Kawano A, Ooho A, Azuma K, Kato M, Shimoda S, Hayashi J, Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real-world cohort study, Hepatology Research, 10.1111/hepr.13328, 49, 6, 617-626, 2019.06. |
15. |
Eiichi Ogawa, Norihiro Furusyo, Koichi Azuma, Makoto Nakamuta, Hideyuki Nomura, Kazufumi Dohmen, Takeaki Satoh, Akira Kawano, Toshimasa Koyanagi, Aritsune Ooho, Kazuhiro Takahashi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Elbasvir plus Grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease, Antiviral Research, 10.1016/j.antiviral.2018.10.003, 159, 143-152, 2018.11. |
16. |
Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J, Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment, ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 10.1111/apt.14380, 47, 1, 104-113, 2018.01. |
17. |
Ogawa E, Furusyo N, Murata M, Toyoda K, Hayashi T, Ura K, Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV, LIVER INTERNATIONAL, 10.1111/liv.13496, 38, 1, 76-83, 2018.01. |
18. |
Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazufumi Dohmen, Nobuhiko Higashi, Kazuhiro Takahashi, Akira Kawano, Koichi Azuma, Takeaki Satoh, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b, Journal of Gastroenterology, 52, 7, 845-854, 2017.07. |
19. |
Eiichi Ogawa, Norihiro Furusyo, Masayuki Murata, Motohiro Shimizu, Toyoda Kazuhiro, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV assays for the monitoring of sofosbuvir-based therapy, Antiviral Therapy, 10.3851/IMP3085, 22, 1, 61-70, 2017.03. |
20. |
Eiichi Ogawa, Norihiro Furusyo, Naoki Yamashita, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Makoto Nakamuta, Takeaki Satoh, Hideyuki Nomura, Koichi Azuma, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of daclatasvir plus asunaprevir for HCV genotype 1b patients aged 75 and over with or without cirrhosis, Hepatology Research, doi: 10.1111/hepr.12738, 47, 3, E120-E131, 2017.03. |
21. |
Eiichi Ogawa, Norihiro Furusyo, Hideyuki Nomura, Kazuhiro Takahashi, Nobuhiko Higashi, Akira Kawano, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Masaki Kato, Shinji Shimoda, Eiji Kajiwara, Jun Hayashi, Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis, Antiviral Research, 24, 136, 37-44, 2016.12. |
22. |
Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Takeo Hayashi, Motohiro Shimizu, Haru Mukae, Kazuhiro Toyoda, Taeko Hotta, Takeshi Uchiumi, Jun Hayashi, Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy, Antiviral Research, 126, 35-42, 2016.02. |
23. |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection, Journal of Gastroenterology and Hepatology, 30, 12, 1759-1767, 2015.12. |
24. |
Eiichi Ogawa, Norihiro Furusyo, Kazufumi Dohmen, Eiji Kajiwara, Akira Kawano, Hideyuki Nomura, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure, Journal of Viral Hepatitis, 22, 12, 992-1001, 2015.12. |
25. |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Comparative safety study on severe anemia by simeprevir- versus telaprevir-based triple therapy for chronic hepatitis C, Journal of Gastroenterology and Hepatology, doi: 10.1111/jgh.12945., 30, 8, 1309-1316, 2015.08. |
26. |
Eiichi Ogawa, Norihiro Furusyo, Motohiro Shimizu, Takeshi Ihara, Takeo Hayashi, Yuji Harada, Kazuhiro Toyoda, Murata Masayuki, Jun Hayashi, Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C, ANTIVIRAL THERAPY, 20, 185-192, 2015.05. |
27. |
Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Tomohiko Akahoshi, Yoshihiko Maehara, Jun Hayashi, Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis, Journal of Gastroenterology and Hepatology, 29, 1728-1735, 2014.09. |
28. |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Makoto Nakamuta, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection, Antiviral Research, 104, 102-109, 2014.04. |
29. |
Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: A prospective clinical study , Alimentary Pharmacology and Therapeutics, 38, 9, 1076-1085, 2013.11. |
30. |
Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy, Journal of Hepatology, 59, 4, 667-674, 2013.09. |
31. |
Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Kazuhiro Toyoda, Kunimitsu Eiraku, Motohiro Shimizu, Yuji Harada, Fujiko Mitsumoto, Koji Takayama, Okada Kyoko, Mosaburo Kainuma, Jun Hayashi, Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays, Antiviral Research, 99, 2, 119-124, 2013.08. |
32. |
Eiichi Ogawa, Norihiro Furusyo, Murata Masayuki, Hiroaki Ikezaki, Takeshi Ihara, Takeo Hayashi, Kazuhiro Toyoda, Okada Kyoko, Mosaburo Kainuma, Eiji Kajiwara, Kazuhiro Takahashi, Takeaki Satoh, Jun Hayashi, Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia, Journal of Viral Hepatitis, 20, 12, 838-846, 2013.12. |
33. |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Toshihiro Maruyama, Yuichi Tanabe, Takeaki Satoh, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: A prospective, multicenter study, Journal of Hepatology, 58, 3, 495-501, 2013.03. |
34. |
Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J, Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1, Journal of Hepatology, 57, 3, 534-540, 2012.09. |
35. |
Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin., Journal of Infection and Chemotherapy, DOI: 10.1007/s10156-012-0396-5, 18, 5, 689-697, 2012.10. |
36. |
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; The Kyushu University Liver Disease Study (KULDS) Group., An evaluation of the adverse effect of premature discontinuation of pegylated interferon alpha-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study (KULDS), Journal of Gastroenterology and Hepatology, 27, 7, 1233-1240, 2012.07. |
37. |
Ogawa E, Furusyo N, Murata M, Ohnishi H, Toyoda K, Taniai H, Ihara T, Ikezaki H, Hayashi T, Kainuma M, Hayashi J., Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog, Hepatology Research, 41, 12, 1178-88, 2011.12. |
38. |
Ogawa E, Furusyo N, Toyoda K, Taniai H, Otaguro S, Kainuma M, Murata M, Sawayama Y, Hayashi J., Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b and ribavirin treatment., BMC Gastroenterology, 10, 38, 2010.04. |
39. |
Ogawa E, Furusyo N, Toyoda K, Takeoka H, Maeda S, Hayashi J., The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients with treated with pegylated interferon alpha-2b and ribavirin., Antiviral Research, 83, 2, 127-134, 2009.04. |
40. |
Ogawa E, Furusyo N, Toyoda K, Takeoka H, Otaguro S, Hamada M, Murata M, Sawayama Y, Hayashi J., Transient elastography for patients with chronic hepatitis B and C virus infection: A noninvasive, quantitative assessment of liver fibrosis., Hepatology Research, 37, 12, 1002-1010, 2007.12. |